Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus
Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A
The Cochrane database of systematic reviews · 142 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2008-01-23 · Cochrane Database Syst Rev · vol. 2009 · número 1 · pág. CD003205
- Editorial
- Elsevier BV
- Citado
- 282 citas · más que el 99% de estudios similares · 14.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 134 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Fatty Acid Research and Health · Nutritional Studies and Diet · Diabetes Treatment and Management
- Palabras clave
- omega-3 polyunsaturated fatty acids, type 2 diabetes, triglycerides, VLDL cholesterol, LDL cholesterol, HDL cholesterol, glycemic control, HbA1c, cardiovascular risk, dietary supplementation, hypertriglyceridemia, cardiovascular outcomes, body weight, insulin, adverse effects, omega-3 deficiency
- MeSH
- humans, diabetes mellitus, type 2, fatty acids, omega-3, triglycerides, plant oils, cross-over studies, cholesterol, ldl, hyperlipidemias, randomized controlled trials as topic
6 autores
- Janine Hartweg🇬🇧University of Oxford
- Rafael Perera🇬🇧University of Oxford
- Víctor M. Montori🇺🇸Mayo Clinic
- Seán F. Dinneen🇮🇪University Hospital Galway
- Andrew Neil🇬🇧University of Oxford
- Andrew J Farmer🇬🇧University of Oxford
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
People with type 2 diabetes mellitus are at increased risk from cardiovascular disease. Dietary omega-3 polyunsaturated fatty acids (PUFAs) are known to reduce triglyceride levels, but their impact on cholesterol levels, glycemic control and vascular outcomes are not well known.
Objectives
To determine the effects of omega-3 PUFA supplementation on cardiovascular outcomes, cholesterol levels and glycemic control in people with type 2 diabetes mellitus.
Search strategy
We carried out a comprehensive search of The Cochrane Library, MEDLINE, EMBASE, bibliographies of relevant papers and contacted experts for identifying additional trials.
Selection criteria
All randomised controlled trials were included where omega-3 PUFA supplementation or dietary intake was randomly allocated and unconfounded in people with type 2 diabetes. Authors of large trials were contacted for missing information.
Data collection and analysis
Trials were assessed for inclusion. Authors were contacted for missing information. Data was extracted and quality assessed independently in duplicate. Fixed-effect meta-analysis was carried out.
Main results
Twenty three randomised controlled trials (1075 participants) were included with a mean treatment duration of 8.9 weeks. The mean dose of omega-3 PUFA used in the trials was 3.5 g/d. No trials with vascular events or mortality endpoints were identified. Among those taking omega-3 PUFA triglyceride levels were significantly lowered by 0.45 mmol/L (95% confidence interval (CI) -0.58 to -0.32, P < 0.00001) and VLDL cholesterol lowered by -0.07 mmol/L (95% CI -0.13 to 0.00, P = 0.04). LDL cholesterol levels were raised by 0.11 mmol/L (95% CI 0.00 to 0.22, P = 0.05). No significant change in or total or HDL cholesterol, HbA1c, fasting glucose, fasting insulin or body weight was observed. The increase in VLDL remained significant only in trials of longer duration and in hypertriglyceridemic patients. The elevation in LDL cholesterol was non-significant in subgroup analyses. No adverse effects of the intervention were reported.
Authors' conclusions
Omega-3 PUFA supplementation in type 2 diabetes lowers triglycerides and VLDL cholesterol, but may raise LDL cholesterol (although results were non-significant in subgroups) and has no statistically significant effect on glycemic control or fasting insulin. Trials with vascular events or mortality defined endpoints are needed.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.